Geneva, Switzerland, June 24, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), and the CIRI (International Center for Infectiology Research), in Lyon, France, a world-class research institute against infectious diseases, announced today the signing of an extension to their existing Research Collaboration Agreement.
https://geneuro.ch/data/news/2021.06.24-GeNeuro-PR-CIRI-new-agreement-EN-vf-1-.pdf
.